AMRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Amneal Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$19.36+0.18 (+0.94%)
Close on Oct 19, 2026
- Market cap
- $6.35B
- P/E (TTM)
- 39.5
- Dividend yield
- –
Share price
+$9.44 (+95.16%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Amneal Pharmaceuticals, Inc. grew revenue 9.3% to $3.12B over the twelve months to Jun 30, 2026. Operating income rose 20.6% to $453.92M, moving the operating margin from 13.2% to 14.6%. Free cash flow was $127.84M, down 54.8% from a year earlier.
Revenue
$3.12B
+9.3% vs. a year earlier
Operating income
$453.92M
+20.6% vs. a year earlier
Free cash flow
$127.84M
-54.8% vs. a year earlier
EPS, diluted
$0.49
+4800.0% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $6.35B
- P/E ratio
- 39.5
- Price to sales
- 2.04
- Price to book
- 192.35
- Dividend yield
- –
- Free cash flow yield
- 2.01%
Fundamentals
- Revenue
- $3.12B
- Net income
- $157.36M
- EPS, diluted
- $0.49
- Free cash flow
- $127.84M
- Book value per share
- $0.10
- Diluted shares
- 328M
Eleven years at a glance
Fiscal years 2015 to 2025 and trailing twelve months, USD
Revenue
$3.12B+9.3% YoY
Gross profit
$1.23B+14.1% YoY
Operating income
$453.92M+20.6% YoY
Net income
$157.36M+4562.6% YoY
EPS, diluted
$0.49+4800.0% YoY
Free cash flow
$127.84M-54.8% YoY
Reported periodTrailing twelve months